Our research team consists of several physicians, two clinical psychologists, three (bio)engineers, a nurse/case manager, and an office manager.
Cancer treatment during pregnancy is discussed and scheduled in concert with specialists from related disciplines. In a multidisciplinary clinical setting, the primary focus is on optimal maternal cancer treatment and fetal well-being. In parallel and where applicable, research items are addressed. For example, children are followed on a regular basis in order to assess the effects, if any, of antenatal exposure to cancer treatment. This strategy has resulted in good clinical experience and very reliable scientific data.
Since its founding, the team has published 47 scientific papers on cancer and pregnancy and has delivered more than 80 talks on the topic, both internationally and nationally.
KU Leuven is Belgium’s largest and oldest university. UZ Leuven is its network of research hospitals but functions as an autonomous healthcare provider. UZ Leuven is among Europe’s largest hospital systems.
Additional information can be obtained through this website.
Frédéric Amant, MD, PhD (°1967), received his medical degree from the University of Leuven (KU Leuven), Belgium in 1992, completed his specialty training as an obstetrician/gynecologist in 1998, and his subspecialty training in gynecologic oncology in 2000. He is professor at the KU Leuven, Belgium and heads the scientific section of this specialty.
Since July 1st 2015 he works as a specialist in gynecologic oncology in “Antoni Van Leeuwenhoek”-hospital (AVL-NKI) in Amsterdam. He will stop his clinical activities in the University Hospitals (UZ Gasthuisberg) Leuven for the next 2 years, but remains the principal investigator of the cancer in pregnancy research project in Leuven.
Frédéric Amant heads the International Network on ‘Cancer, Infertility and Pregnancy’ (INCIP) of the European Society of Gynecologic Oncology (ESGO) (www.cancerinpregnancy.org). He chairs the Endometrium Tumor Site Committee of the European Organization for Research and Treatment of Cancer (EORTC), Gynecologic Cancer Group. He is chair of the European Network Individualized Treatment Endometrial Cancer (ENITEC), a task force within the ESGO.
Frédéric Amant, M.D., Ph.D.
Department of Oncology, KU Leuven
Department of Gynaecological Oncology, UZ Leuven
Herestraat 49, 3000 Leuven, Belgium
Tel:+32 16 34 42 52
Fax:+32 16 34 42 05
- Kristel Van Calsteren, M.D., Ph.D., Obstetrics & Gynaecology, UZ Leuven, KU Leuven
- Liesbeth Lenaerts, Ph.D, Bio-engineer, Obstetrics & Gynaecology, KU Leuven
- Tineke Vandenbroucke, Msc, Obstetrics & Gynaecology, UZ Leuven, KU Leuven
- Magali Verheecke, M.D., Obstetrics & Gynaecology, UZ Leuven, KU Leuven
- Jorine de Haan, M.D., Obstetrics & Gynaecology, KU Leuven
- Jeroen Blommaert, Engineer, Medical Imaging, UZ Leuven, KU Leuven
- Jelle Stans, Biomedical Scientist, UZ Leuven, KU Leuven
- Hanne Lefrère, Bio-engineer, Obstretrics & Gynaecology, KU Leuven
- Laura van Dam, Student in Medicine, Obstetrics & Gynaecology, UZ Leuven
- Liesbeth Leemans, Case Manager, Obstetrics & Gynaecology, UZ Leuven
- Marie-Astrid Vanhoorick, Secretariat Obstetrics & Gynaecology, UZ Leuven
- Diane Wolput, Secretariat Obstetrics & Gynaecology, UZ Leuven
- Griet Demulder, Consultant